Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease

NCT07306104 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-02-16
Last updated
2026-04-29

Condition(s) studied

PARKINSON DISEASE (Disorder)

Investigational drug(s) / intervention(s)

Transcranial pulsed electromagnetic fields (T-PEMF)Sham (No Treatment)

Transcranial pulsed electromagnetic fields (T-PEMF): 30 min daily stimulation with transcranial pulsed electromagnetic fields (50 Hz)

Sham (No Treatment): 30 min daily the participants are using/wearing the T-PEMF device but no stimulation occurs

Study summary

The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:

* How does 6 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease?
* How does 12 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?

The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.

Participants in the intervention group will:

* receive one 30 min treatment session daily for 12 months
* receive either T-PEMF or sham treatment for the first 6 months
* receive active T-PEMF treatment the last 6 months
* visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Intervention Groups Inclusion Criteria: * Diagnosed with idiopathic Parkinson's disease * The participant must be able to understand, accept, and complete the planned procedures * Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2 * Mini Mental-State Examination score \> 22 Exclusion Criteria: * Cancer in the brain, neck, or head area * Presence of active medical implants * Epilepsy * Alcoholism * Substance abuse * Open wound on the scalp * Severe psychopathological disorders * Pregnancy * Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment * Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep * Neurological disease other than Parkinson's disease * Previous stroke * Reduced motor function caused by conditions other than Parkinson's disease Control Group with Parkinson's Disease Inclusion Criteria: * Diagnosed with idiopathic Parkinson's disease * The patient must be able to understand, accept, and complete the planned procedures * Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2 * Mini Mental-State Examination score \> 22 Exclusion Criteria: * Neurological disease other than Parkinson's disease * Reduced motor function caused by conditions other than Parkinson's disease Healthy Reference Group: Inclusion Criteria: -The patient must be able to understand, accept, and complete the planned procedures Exclusion Criteria: * Neurological disease * Reduced motor function caused by condition

Primary outcome measure(s)

  • Sit-to-stand — From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
    Completion time of 5 repetition sit-tot-stand test at maximal speed performed on force plate.

Trial sites (2)

FacilityCityRegionStatus
Odense University Hospital Odense Denmark Recruiting
University of Southern Denmark Odense Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07306104 on ClinicalTrials.gov ↗ ← All trials in Denmark